ProShare Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

ProShare Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,135	Closed	-$8K	–	1711
2019 Q2	$8K	Sell	1,135 -30	-3%	-$257	﹤0.01%	1620
2019 Q1	$10K	Buy	1,165 +32	+3%	+$330	﹤0.01%	1654
2018 Q4	$18K	Sell	1,133 -138	-11%	-$3.04K	﹤0.01%	1560
2018 Q3	$42K	Sell	1,271 -68	-5%	-$1.75K	﹤0.01%	1735
2018 Q2	$30K	Buy	+1,339	New	+$31.7K	﹤0.01%	1774
2014 Q2	–	Sell	-5,250	Closed	-$78K	–	2682
2014 Q1	$78K	Buy	+5,250	New	+$94.3K	﹤0.01%	2706
2013 Q4	–	Sell	-5,128	Closed	-$106K	–	2074
2013 Q3	$106K	Buy	5,128 +1,153	+29%	+$26.4K	﹤0.01%	2403
2013 Q2	$99K	Buy	+3,975	New	+$170K	﹤0.01%	2258

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

ProShare Advisors's AVEO Position: Q3 2019 in Review

ProShare Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2019, closing a stake of 1,135 shares — an estimated $8K sold.

ProShare Advisors first reported a position in AVEO in Q2 2013 and held it in 8 quarters. The position peaked at $106K in Q3 2013. 59 funds tracked by Wall St. Rank hold AVEO as of Q3 2019.

ProShare Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
ProShare Advisors sold 1,135 AVEO Pharmaceuticals, Inc. shares in Q3 2019, an estimated $8K.
ProShare Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 8 quarters.
ProShare Advisors's AVEO Pharmaceuticals, Inc. position peaked at $106K in Q3 2013.
59 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2019.

Based on ProShare Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.